Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Adenocarcinoma Metastatic 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 212Irinotecan 145Leucovorin 139Gemcitabine 124S 1 (combination) 110apatinib 109Cisplatin 102Drug Therapy 98Bevacizumab 98Radiotherapy 97Paclitaxel 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 53toripalimab 52Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × sapropterin × Gastrointestinal × Clear all
NCT06396637 2024-05-02

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

Sun Yat-sen University

Phase 2 Unknown
20 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡